欧林生物：四价流感病毒裂解疫苗启动Ⅲ期临床试验

Core Viewpoint - The company has officially launched Phase III clinical trials for its quadrivalent influenza virus split vaccine (MDCK cells) based on previous clinical trial results and has completed the enrollment of the first subject [1] Group 1 - The quadrivalent influenza virus split vaccine is designed to enhance immunogenicity and provide broader protection against influenza strains [1] - The initiation of Phase III clinical trials marks a significant milestone in the vaccine development process, indicating progress towards potential market approval [1] - The completion of the first subject enrollment demonstrates the company's commitment to advancing its vaccine pipeline and addressing public health needs [1]